

Stahl's Illustrated

Index

- acetylcholine 44, 45
 - anticholinergics 76, 126, 137
- activation (side effect) 125
- adverse effects 124, 137
 - in bipolar depression 96
- agomelatine 91
- allopregnanolone 95
- alpha-1 receptor antagonism 126
- alpha-2 adrenergic receptors 25, 46
 - antagonists 48, 92
- amygdala 17
- analgesia 84
- anticoagulants 125
- anticonvulsants 104
 - carbamazepine 117
 - lamotrigine 105, 118, 145
 - valproate 106, 116
- antidepressants
 - for bipolar depression 96, 145, 148, 149
 - future prospects 151
 - ketamine 129, 149
 - MAOIs 135, 138
 - for mixed depression 96, 108
 - modafinil 134, 148
 - monitoring and time course 123
 - mood stabilizers 102, 131, 145
 - multidrug combinations 107, 128, 145
 - NDRIs 86, 132, 152
 - for resistant depression
 - bipolar 145, 148, 149
 - unipolar 128
 - SARIs 89, 133
 - serotonin/dopamine blockers 97, 108, 128, 145
 - side effects 96, 124, 137
 - SNRIs 82, 125, 132
 - SPARIs 80
 - SSRIs 72, 88, 125, 132
 - steroids 94
 - TCA's 135
 - for unipolar depression 71, 128
- anxiety 122
- anxiolytics 75, 77, 131
- aripiprazole 113, 128
- arousal combinations 134
- asenapine 113
- benzodiazepines 52
- bipolar disorder
 - classification 1
 - diagnosis 7
 - progression 9
 - symptoms of mania 4, 62
 - treatment of depression 96
 - bright light therapy 147, 159
 - ECT 146
 - ketamine 149

- bipolar disorder (cont.)
 - modafinil 148
 - mood stabilizers 102, 145
 - multidrug combinations 107, 145
 - psychotherapy 140
 - resistant depression 144
 - serotonin/dopamine blockers 97, 145
 - treatment of mania
 - mood stabilizers 114
 - multidrug combinations 119
 - serotonin/dopamine blockers 112
- brain stimulation techniques 142, 146, 160
- brain-derived neurotrophic factor (BDNF) 12
- brexanolone 95
- brexipiprazole 128
- bright light therapy 147, 159
- bupropion 87, 152
- bupirone 131

- California rocket fuel 133
- carbamazepine 117
- cariprazine 100, 110, 113, 128
- catechol-O-methyltransferase (COMT) 33
- circadian rhythm abnormalities 20
 - treatment 91, 147, 159
- citalopram 78
- classification 1
- cranial electrotherapy (CES) 160
- cytokines 18

- DA *see* dopamine
- definitions 1
- depression
 - classification 1
 - diagnosis 3, 7
 - disease models 10
 - with mixed features 6
 - treatment 96, 108
 - mood disorder spectrum 2, 5
 - neural circuits 63
 - pathophysiology *see* pathophysiology
 - progression 9
 - symptoms 3, 63, 122
- depression, treatment
 - bipolar *see* bipolar disorder, treatment of depression
 - brain stimulation techniques 142, 146, 160
 - definitions of success/failure 67
 - exercise 163
 - future prospects 151
 - mixed depression 96, 108
 - monitoring and time course 123
 - pharmacological *see* antidepressants
 - psychotherapy 140, 154, 158
 - remission 68, 70, 121
 - residual symptoms 122
 - unipolar *see* unipolar depression, treatment
- desvenlafaxine 83
- dextromethorphan 152
- diagnosis 3, 7
 - see also* symptoms
- dopamine (DA) 31
 - and 5HT1A receptors 45
 - in mania 112
 - and MAOIs 138
 - neural pathways 31
 - receptors 34
 - synthesis 32
 - termination of action 33
- dopamine reuptake inhibitors (NDRIs) 86
 - in drug combinations 132, 152
- dopamine transporter inhibition 75, 87, 148

- dopamine/serotonin blockers
 - see serotonin/
 - dopamine blockers
- duloxetine 84
- ecstasy (MDMA) 155
- electroconvulsive therapy (ECT) 146, 160
- escitalopram 79
- esketamine 129
- esmethadone 153
- etiology 10
- exercise 163
- family history 8
- 5HT (5-hydroxytryptamine)
 - see serotonin
- fluoxetine 74
- fluoxetine-olanzapine 97, 128
- flvoxamine 77
- GABA (gamma-aminobutyric acid)
 - GABAergic interneurons 39
 - receptors 51
 - GABAA 52, 94
 - synthesis 49
 - termination of action 50
- genetics 127
- glucocorticoids 17
- glutamate
 - and ketamine 130
 - and lamotrigine 105
 - neural pathways 55
 - receptors 60
 - recycling 56
 - regulation of release 38
- growth factors (BDNF) 12
- hallucinogen-assisted
 - psychotherapy 154
- headache 125
- hippocampus 17
- histamine antagonism 126
- history 8
- hypertension 139
- hypomania 1
- hypothalamic-pituitary-adrenal (HPA) axis 16
- inflammation (neuronal) 18
- insomnia 20, 90
- ketamine 129, 149
- lamotrigine 105, 118, 145
- levomilnacipram 85
- lithium
 - for depression 103, 131
 - for mania 115
- lumateperone 101, 111, 128
- lurasidone 99, 109
- major depressive disorder
 - see depression
- mania 1
 - with mixed features 6
 - mood disorder spectrum 2, 5
 - symptoms 4, 62
 - treatment
 - mood stabilizers 114
 - multidrug combinations 119
 - serotonin/dopamine blockers 112
- melatonin receptors 91
- methadone 153
- 3,4-methylene-
 - dioxymethamphetamine (MDMA) 155
- microglia 18
- S-milnacipram 85
- mirtazapine 92, 133
- mixed features 1, 5
 - progression 9
 - symptoms 6

- mixed features (cont.)
 - treatment of depression 96, 108
- modafinil 134, 148
- models of disease 10
- monoamine oxidase A and B (MAO-A/MAO-B) 24, 28, 33
- monoamine oxidase inhibitors (MAOIs) 135, 138
- monoamines
 - disease models 11
 - see also dopamine; norepinephrine; serotonin
- mood stabilizers
 - carbamazepine 117
 - for depression 102
 - resistant 131, 145
 - lamotrigine 105, 118, 145
 - lithium 103, 115, 131
 - for mania 114
 - valproate 106, 116
- nausea 125
- NDRI (norepinephrine-dopamine reuptake inhibitors) 86
 - in drug combinations 132, 152
- NE see norepinephrine
- neuroactive steroids 94
- neuroinflammation 18
- neuroplasticity model 13
- neuroprogression model 14
- neurotransmitters
 - disease models 11
 - pathophysiology 21
 - and symptoms 66
 - see also individual neurotransmitters
- NMDA receptor antagonists 151
 - dextromethorphan 152
 - esmethadone 153
 - ketamine 129, 149
- norepinephrine (NE)
 - neural pathways 22
 - receptors 25, 46, 92
 - regulation by 5HT receptors 44, 45
 - synthesis 23
 - termination of action 24
- norepinephrine reuptake inhibitors 74, 82, 125, 132
- norepinephrine-dopamine reuptake inhibitors (NDRIs) 86
 - in drug combinations 132, 152
- olanzapine 113
- olanzapine-fluoxetine 97, 128
- pain relief 84
- paroxetine 76
- pathophysiology 21
 - disease models 10
 - dopamine 31, 45
 - GABA 49
 - glutamate 38, 55
 - norepinephrine 22, 44
 - serotonin & its receptors 26, 36
- personalized medicine 127
- pharmacogenetics 127
- physical exercise 163
- psilocybin 156
- psychotherapy 140, 158
 - hallucinogen-assisted 154
- quetiapine 98, 113, 128
- quinidine 152
- relapse 69, 70
- remission 68, 70, 121
 - residual symptoms 122
- resistant depression
 - bipolar 144
 - bright light therapy 147

- ECT 146
- ketamine 129, 149
- MAOIs 135, 138
- modafinil 148
- multidrug combinations 128, 145
- psychotherapy 140, 158
- TCA's 135
- TMS 142
- unipolar 127
- response (definition) 67
- risperidone 113

- SARIs (serotonin antagonist/reuptake inhibitors) 89, 133
- sedation (side effect) 126
- selective serotonin reuptake inhibitors (SSRIs) 72
 - citalopram 78
 - in drug combinations 132
 - escitalopram 79
 - fluoxetine 74
 - fluoxetine-olanzapine 97, 128
 - fluvoxamine 77
 - mechanism of action 73, 88
 - paroxetine 76
 - sertraline 75
 - side effects 125
- serotonin (5HT) 26
 - neural pathways 26
 - and other neurotransmitters 30, 38
 - receptors 29, 36
 - serotonin syndrome 139
 - synthesis 27
 - termination of action 28
- serotonin antagonist/reuptake inhibitors (SARIs) 89, 133
- serotonin/dopamine blockers
 - aripiprazole 113, 128
 - for bipolar depression 97, 145
 - brexipiprazole 128
 - cariprazine 100, 110, 113, 128
 - lumateperone 101, 111, 128
 - lurasidone 99, 109
 - for mania 112
 - for mixed depression 108
 - olanzapine-fluoxetine 97, 128
 - quetiapine 98, 113, 128
 - for resistant depression 128, 145
- serotonin-norepinephrine reuptake inhibitors (SNRIs) 82, 125, 132
- serotonin partial agonist reuptake inhibitors (SPARIs) 80
- sertraline 75
- sexual dysfunction 89, 126
- side effects 124, 137
 - in bipolar depression 96
- sigma 1 receptors 75, 77
- sleep disturbances 20, 90
- SNRIs (serotonin-norepinephrine reuptake inhibitors) 82, 125, 132
- SPARIs (serotonin partial agonist reuptake inhibitors) 80
- SSRIs see selective serotonin reuptake inhibitors
- steroids, neuroactive 94
- stimulants 134
- stress response 16
- symptoms 5, 61
 - brain circuits 62, 65
 - depression 3, 63
 - residual (after treatment) 122
 - mania 4, 62
 - mixed features 6
- TCA's (tricyclic antidepressants) 135
- therapeutic targets 1, 61, 66
- thyroid treatment 131

- transcranial magnetic stimulation (TMS) 142, 160
- trazodone 90
- tricyclic antidepressants (TCAs) 135
- tryptophan 27
- tyramine 139
- tyrosine 23, 32

- unipolar depression 1
 - brain circuits 63
 - diagnosis 3, 7
 - progression 9
 - remission 68, 70, 121
 - residual symptoms 122
 - symptoms 3, 63, 122
 - treatment 71
 - future prospects 151
 - MAOIs 135, 138
 - monitoring and time course 123
 - multidrug combinations 128
 - NDRI 86, 132, 152
 - pharmacogenetics 127
 - psychotherapy 140, 158
 - of resistant depression 127
 - SARIs 89, 133
 - SNRIs 82, 125, 132
 - SPARIs 80
 - SSRIs 72, 88, 125, 132
 - steroids 94
 - TCAs 135
 - TMS 142

- valproate 106, 116
- venlafaxine 83
- vilazodone 81
- voltage-sensitive sodium channels (VSSCs) 105, 116, 117, 137
- vortioxetine 93

- weight gain 126

- ziprasidone 113
- zuranolone 95